$APGE News
Last published 2mo ago
- 2mo agoABBVAPGEAbbVie Completes Acquisition of Apogee TherapeuticsPR NewswireAbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the...
- 3mo agoAPGEApogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline UpdatesGlobeNewswireAbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2
- 4mo agoABBVAPGEAbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioPR NewswireAbbVie (NYSE: ABBV) and Apogee Therapeutics (NASDAQ: APGE) ("Apogee") today announced they have entered into a definitive agreement under which...
- 4mo agoABBVAPGEAbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioPR NewswireAbbVie (NYSE: ABBV) and Apogee Therapeutics (NASDAQ: APGE) ("Apogee") today announced they have entered into a definitive agreement under which...
- 5mo agoAPGEApogee Therapeutics to Participate in Upcoming June ConferencesGlobeNewswireSAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Jefferies Global
- 5mo agoAPGEApogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of ZumilokibartGlobeNewswireUp to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt Combined with company's current total cash of $1.3
- 5mo agoAPGEApogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic DermatitisGlobeNewswireAPEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart
- 5mo agoAPGEApogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026GlobeNewswireSAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles
- 6mo agoAPGEApogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial ResultsGlobeNewswireZumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:- APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy
- 7mo agoAPGEApogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 MillionGlobeNewswireSAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class
- 7mo agoAPGEApogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public OfferingGlobeNewswireSAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class
- 7mo agoAPGEApogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public OfferingGlobeNewswireSAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class
- 7mo agoAPGEApogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic DermatitisGlobeNewswireAPEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% patients maintained EASI-75- 86% and 78% patients maintained vIGA
- 8mo agoAPGEApogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial ResultsGlobeNewswireZumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway:- APEX Phase 2 Part A 52-week data expected this month- APEX Phase 2 Part B 16-week data expected
- 8mo agoAPGEApogee Therapeutics to Participate in Upcoming March ConferencesGlobeNewswireSAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health
- 8mo agoAMGNCNTBNKTRAPGE+6Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsightPR NewswireRecently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment practices, atopic dermatitis...
- 9mo agoAPGEApogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireSAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook:
- 10mo agoAPGEApogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026GlobeNewswireSAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles
- 1y agoAPGEApogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial ResultsGlobeNewswirePipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026,
- 1y agoAPGEApogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP AntibodyGlobeNewswireInterim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month
- 1y agoAPGEApogee Therapeutics to Participate in Upcoming ConferencesGlobeNewswireSAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2nd
- 1y agoAPGEApogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 MillionGlobeNewswireSAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles
- 1y agoAPGEApogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public OfferingGlobeNewswireSAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles
- 1y agoAPGEApogee Therapeutics, Inc. Announces Proposed Underwritten Public OfferingGlobeNewswireSAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles
- 1y agoAPGEApogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 CongressGlobeNewswireSAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class
- 1y agoAPGEApogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation ForumGlobeNewswireSAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual
- 1y agoAPGEApogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial ResultsGlobeNewswirePositive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every
- 1y agoAPGEApogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic DermatitisGlobeNewswireAPEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week
- 1y agoAPGEApogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025GlobeNewswireSAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and
- 1y agoAPGEApogee Therapeutics to Participate at the Jefferies Global Healthcare ConferenceGlobeNewswireSAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare
- 1y agoAPGEApogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial ResultsGlobeNewswirePhase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in mild-to-moderate
- 1y agoAPGEApogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate AsthmaGlobeNewswireMultiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated
- 1y agoAPGEApogee Therapeutics to Participate at the Bank of America 2025 Health Care ConferenceGlobeNewswireSAN FRANCISCO and BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May
- 1y agoAPGEApogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial ResultsGlobeNewswireAccelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990) Phase 1b
- 1y agoAPGEApogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)GlobeNewswireInterim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 (APG777 + APG990) Phase 1b head-to-head study vs.
- 1y agoAPGEApogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025GlobeNewswireSAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and
- 1y agoAPGEApogee Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswireSAN FRANCISCO and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE) today announced that members of management will participate at the following investor conferences. TD Cowen 45th
- 1y agoAPGEApogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic DermatitisGlobeNewswireEnrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE
- 1y agoAPGEApogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech ConferenceGlobeNewswireSAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech
- 1y agoAPGEApogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I ConditionsGlobeNewswireInterim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus monotherapy
- 1y agoAPGEApogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D DayGlobeNewswirePositive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers Data
- 1y agoAPGEApogee Therapeutics Announces Agenda for Virtual R&D DayGlobeNewswireSAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy
- 1y agoAPGEApogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024GlobeNewswireSAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy
- 1y agoAPGEApogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial ResultsGlobeNewswireContinued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2 Part A data for
- 2y agoAPGEApogee Therapeutics to Participate in Upcoming November Investor ConferencesGlobeNewswireSAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy
- 2y agoAPGEApogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory DiseasesGlobeNewswirePharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently approved treatments for
- 2y agoAPGEApogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific MeetingGlobeNewswireSAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy
- 2y agoAPGEApogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation SummitGlobeNewswireSAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy
- 2y agoAPGEApogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial OfficerGlobeNewswireSAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy
- 2y agoAPGEApogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesGlobeNewswireInterim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential